Tampa, FLNCT04245397Now EnrollingIRB Ready

Myelodysplastic Syndromes Clinical Trial in Tampa, FL

Access cutting-edge myelodysplastic syndromes treatment through this clinical trial at a research site in Tampa. Study-provided care at no cost to qualified participants.

Sponsored by Syntrix Biosystems, Inc.

Quick Self-Assessment

See if you qualify for this Tampa location

Preparing your pre-screening questions…

Expert Care in Tampa

Access myelodysplastic syndromes specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related myelodysplastic syndromes treatment provided free

Apply for This Tampa Location

Check if you qualify for this myelodysplastic syndromes clinical trial in Tampa, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Tampa

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Tampa site if eligible
  4. 4Begin participation

About This Myelodysplastic Syndromes Study in Tampa

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

Sponsor: Syntrix Biosystems, Inc.

Who Can Participate

Inclusion Criteria

Diagnosis of MDS by World Health Organization criteria, and either
International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk patients without 5q deletion: i. Dose escalation portion: failed prior treatment with at least 4 cycles started of a hypomethylating agent (HMA; azacitidine or decitabine) defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy. ii. Dose expansion portion: failed prior treatment defined as no response to treatment with at least 4 cycles started of HMA, loss of response at any time point, or progressive disease/intolerance to therapy ("HMA failure"); or no prior treatment with HMA ("HMA naive").
IPSS low risk or intermediate-1 risk patients with 5q deletion: i. Dose escalation portion: failed prior treatment with at least 4 cycles started of lenalidomide and 4 cycles of hypomethylating agent (azacitidine or decitabine) defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy. ii. Dose expansion portion: same as non-del(5q) lower risk cohort + requirement of failed prior treatment with lenalidomide defined as no response to treatment with at least 4 cycles started of lenalidomide, loss of response at any time point, or progressive disease/intolerance to therapy.
IPSS intermediate-2 risk or high risk patients: HMA failure or HMA naïve as defined above.
Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2
Screening laboratory values:
Renal glomerular filtration rate (GFR) ≥ 30 ml/min;
Aspartate aminotransferase (AST) / Alanine aminotransferase (ALT) ≤ 3.0 times upper limit of normal;
Bilirubin \< 1.5 times upper limit of normal;
No history of HIV being HIV positive;
No active Hepatitis B or Hepatitis C infection.
Life expectancy ≥ 12 weeks.
Women of childbearing potential (WOCBP) must use study specified contraception.
WOCBP demonstrate negative pregnancy test.
Not breastfeeding.
Men sexually active must use study specified contraception.

Exclusion Criteria

Use of chemotherapeutic agents or experimental agents for MDS within 14 days of the first day of study drug treatment.
Use of erythroid stimulating agents, Granulocyte-colony stimulating factor (G-CSF), or Granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days of the first day of study drug treatment, or during the study.
Mean triplicate heart rate-corrected QT interval (QTc) \> 500 msec.
Any of the following cardiac abnormalities:
QT interval \> 480 msec corrected using Fridericia's formula;
Risk factors for Torsade de Pointes;
Use of medication that prolongs the QT interval with the exception of drugs that are considered absolutely essential for the care of the subject;
Myocardial infarction ≤ 6 months prior to first day of study drug treatment;
Unstable angina pectoris or serious uncontrolled cardiac arrhythmia.
Any serious or uncontrolled medical disorder.
Prior malignancy within the previous 2 years except for local cancers that have been cured; or patients who have been adequately treated and have low risk of reoccurrence.
Subjects with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses \> 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Use of other investigational drugs within 30 days of study drug administration.
Major surgery within 4 weeks of study drug administration.
Live-virus vaccination within 30 days of study drug administration.
Allergy to study drug component.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Tampa?

Yes, this clinical trial (NCT04245397) has an active research site in Tampa, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Myelodysplastic Syndromes Treatment Options in Tampa, FL

If you're searching for myelodysplastic syndromes treatment options in Tampa, FL, this clinical trial (NCT04245397) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Tampa research site is actively enrolling participants for this clinical trial. You'll receive care from experienced myelodysplastic syndromes specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all myelodysplastic syndromes clinical trials near you to find additional studies recruiting in your area.

More Myelodysplastic Syndromes Trials in Tampa, FL

See all myelodysplastic syndromes clinical trials recruiting in Tampa — not just this study.

Browse Myelodysplastic Syndromes Trials in Tampa →

Browse More Trials by Condition

Myelodysplastic Syndromes TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Tampa?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Tampa, FL